Sara García-Duque

HM Hospitales

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Roberto García‐Leal

Hospital General Universitario Gregorio Marañón

Ana Ortiz de Méndivil

HM Hospitales

C. Fernández-Carballal

Hospital General Universitario Gregorio Marañón

ÁA

Ángel Ayuso‐Sacido

Universidad Francisco de Vitoria

Teresa Panadero

Hospital General Universitario Gregorio Marañón

Cristóbal Belda-Iniesta

Instituto de Salud Carlos III

Fernando Ruiz‐Juretschke

Hospital General Universitario Gregorio Marañón

Arturo Navarro‐Martin

Institut Català d'Oncologia

Martín Antonio

MRC Unit the Gambia

Josefa Carrión-Navarro

Universidad Francisco de Vitoria

Cooperative Institutions

Fundación Kovacs

HM Hospitales

Hospital General Universitario Gregorio Marañón

Fundación Instituto Valenciano de Oncología

Hospital Universitario HM Sanchinarro

Spanish Clinical Research Network

Instituto Ramón y Cajal de Investigación Sanitaria

Hospital Universitario Ramón y Cajal

Hospital Universitario Fundación Jiménez Díaz

Hospital Universitario Puerta de Hierro Majadahonda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Spine Instability Neoplastic Score: agreement across different medical and surgical specialties

The Spine Journal (2015)

Estanislao Arana Francisco M. Kovacs Ana Royuela Beatriz Asenjo Úrsula Pérez‐Ramírez

Cohen's kappa

Specialty

Kappa

10.1016/j.spinee.2015.10.006

Cite

Citations (57)

Brain Arteriovenous Malformations: Impact of Neurologic Status, Bleeding, and Type of Treatment on Final Outcome

Journal of Neurological Surgery Part A Central European Neurosurgery (2020)

Sara García-Duque Roberto García‐Leal Begoña Iza-Vallejo Enrique Castro-Reyes Fernando Fortea

Abstract Background Well-designed studies assessing the treatment outcome of brain arteriovenous malformations (AVMs) are infrequent and have not consistently included all of the available treatment modalities, making their results not completely generalizable. Moreover, the predictors of poor outcome are not well defined. Methods We performed an observational retrospective study of AVM patients. We included patients with clinical, radiologic, and outcome data, with a minimum follow-up of 1 year. Neurologic outcome was documented using the modified Rankin Scale (mRS) at the AVM diagnosis and 30 days after the treatment. Results There were 117 patients, with equal male/female proportion. The mean follow-up time was 51 months. Treatment distribution in the Spetzler–Martin grades I–III was as follows: 52 (54.6%) surgery, 31 (32.35%) radiosurgery, 2 (0.02%) embolization, and 11 (12%) conservative follow-up. Treatment distribution in Spetzler–Martin grades IV and V was as follows: 4 (20%) surgery, 7 (35%) radiosurgery, and 10 (45%) conservative follow-up. Poor neurologic outcome (mRS ≥ 3) was significantly associated with poor clinical status at diagnosis (Glasgow Coma Scale [GCS] score< 14; odds ratio [OR]: 0.20; 95% confidence interval [CI]: 0.001–0.396; p = 0.010). The rupture of the AVM was associated with poor neurologic outcome. The Lawton–Young Supplementary scale (LYSS) proved to be the most effective in predicting poor outcome. The existence of seizures, treatment-related complications, and conservative treatment was associated with the worsening of the mRS score, whereas the existence of hemorrhage was associated with the likelihood of disability. Conclusion Our results suggest that poor neurologic status at diagnosis, AVM rupture, and conservative treatment were associated with worse outcome. Hemorrhage as initial presentation is related to disability, not with mRS worsening. The LYSS appeared to be the best method to predict outcome.

Intracranial Arteriovenous Malformations

Glasgow Outcome Scale

Conservative Treatment

10.1055/s-0040-1714659

Cite

Citations (2)

DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients

Oncotarget (2016)

Noemí Garcia‐Romero Josefa Carrión-Navarro Susana Esteban-Rubio Elisa Lázaro‐Ibáñez Maria Peris‐Celda

Tumor-cell-secreted extracellular vesicles (EVs) can cross the disrupted blood-brain barrier (BBB) into the bloodstream. However, in certain gliomas, the BBB remains intact, which might limit EVs release. To evaluate the ability of tumor-derived EVs to cross the BBB, we used an orthotopic xenotransplant mouse model of human glioma-cancer stem cells featuring an intact BBB. We demonstrated that all types of tumor cells-derived EVs-apoptotic bodies, shedding microvesicles and exosomes-cross the intact BBB and can be detected in the peripheral blood, which provides a minimally invasive method for their detection compared to liquid biopsies obtained from cerebrospinal fluid (CSF). Furthermore, these EVs can be readily distinguished from total murine EVs, since they carry human-specific DNA sequences relevant for GBM biology. In a small cohort of glioma patients, we finally demonstrated that peripheral blood EVs cargo can be successfully used to detect the presence of IDH1G395A, an essential biomarker in the current management of human glioma.

Extracellular Vesicles

Extracellular vesicles

Exosome

Liquid biopsy

10.18632/oncotarget.13635

Cite

Citations (218)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

BMC Medicine (2020)

Noemí Garcia‐Romero Irina Palacín-Aliana Rodrigo Madurga Josefa Carrión-Navarro Susana Esteban-Rubio

Abstract Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment. Results We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo . We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance. Conclusions Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.

10.1186/s12916-020-01610-0

Cite

Citations (26)

Agreement in the assessment of metastatic spine disease using scoring systems

Radiotherapy and Oncology (2015)

Estanislao Arana Francisco M. Kovacs Ana Royuela Beatriz Asenjo Úrsula Pérez‐Ramírez

Specialty

Radiation oncology

Cohen's kappa

10.1016/j.radonc.2015.03.016

Cite

Citations (14)